EUCTR2006-003563-31-NL进行中（未招募）不适用
Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM). - protocol BDR
European Myeloma Network0 个研究点目标入组 90 人开始时间: 2007年5月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Clinicopathological diagnosis of Waldenstrom’s macroglobulinemia as defined by consensus panel one of the Second International Workshop on Waldenstrom’s macroglobulinemia.1 All patients with the diagnosis of WM will be evaluable for response according to the response criteria (section 8.1)
- •No prior systemic treatment for WM. Prior plasmapheresis to control hyperviscosity, is allowed. In that case baseline monoclonal protein levels for assessment of response will be the levels prior to plasmapheresis, if this is the higher value prior to treatment initiation
- •Patients must have at least one of the following indications to initiate treatment as defined by Consensus Panel Two” recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia41.
- •1.Recurrent fever, night sweats, weight loss, fatigue
- •2.Hyperviscosity
- •3.Lympadenopathy which is either symptomatic or bulky (=5cm in maximum diameter)
- •4.Symptomatic hepatomegaly and/or splenomegaly
- •5.Symptomatic organomegaly and/or organ or tissue infiltration
- •6.Peripheral neuropathy due to WM
- •7.Symptomatic cryoglobulinemia
- •8.Cold agglutinin anemia
- •9.Immune hemolytic anemia and/or thrombocytopenia
- •10.Nephropathy related to WM
- •11.Amyloidosis related to WM
- •12.Hemoglobin =10g/dL
- •13.Platelet count <100x109/L
- •14.Serum monoclonal protein >5g/dL even with no symptoms
- •CD20 positive disease based on any previous bone marrow immunohistochemistry or flow cytometric analysis performed up to 3 months prior to enrollment.
- •Karnofsky performance status ?60.
- •Life-expectancy >3 months.
- •Baseline platelet count ? 50?109/L, and absolute neutrophil count ? 0.75?109/L.
- •Meet the following pretreatment laboratory criteria at the Screening visit conducted within 28 days of study enrollment:
- •AST (SGOT): ?3 times the upper limit of institutional laboratory normal.
- •ALT (SGPT): ?3 times the upper limit of institutional laboratory normal.
- •Total Bilirubin: ?2 times the upper limit of institutional laboratory normal, unless clearly related to the disease.
- •Calculated or measured creatinine clearance: ?30 mL/minute.
- •Serum sodium >130 mmol/L.
- •Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Prior systemic treatment with WM (plasmapheresis is allowed)
- •Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
- •Patient has hypersensitivity to dexamethasone, bortezomib, boron or mannitol.
- •Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- •Cardiac amyloidosis
- •Peripheral neuropathy or neuropathic pain grade 2 or higher as defined by NCI CTCAE version 3
- •Women who are pregnant. Women who are breast-feeding and do not consent to discontinue breast-feeding. Women of childbearing age who are not willing to use effective anti-conceptive methods for the duration of the study and 6 months thereafter. Men who do not consent not to father a child during the treatment period and six months thereafter.
研究者
相似试验
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM). - protocol BDREUCTR2006-003563-31-DKEuropean Myeloma Network90
进行中（未招募）
不适用
A phase II Study of Bortezomib (Velcade), a proteasome Inhibitor, in treating patients with idiopathic Myelofibrosis (IM) randomized to receive new investigational drugs. - NDMedDRA version: 6.1Level: PTClassification code 10028537idiopathic myelofibrosisEUCTR2006-001462-16-ITOSPEDALE POLICLINICO S. MATTEO35
招募中
2 期
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom*s Macroglobulinemia: A multicenter Trial of the European Myeloma Networkimmunocytomalymphoplasmacytic lymphomaWaldenstroms Macroglobulinemia10018865NL-OMON30654Academisch Medisch Centrum5
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom’s Macroglobulinemia: A multicenter Trial of the European Myeloma Network - protocole BDRMacroglobulinémie de Waldenström au moment de l’initiation du traitement de 1e ligne.EUCTR2006-003563-31-FRCentre Hospitalier de Lens61
终止
2 期
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular LymphomaLymphoma, FollicularNCT00510887Duke University14